Dendreon (DNDN) Sees Action on Renewed Takeover Speculation
Tweet
Share
E-mail
Get Alerts DNDN Hot Sheet
Join SI Premium – FREE
They're back...
That is takeover rumors on Provenge maker Dendreon (Nasdaq: DNDN).
Today's rumors are vague and come from what would seem to be unreliable sources. Nonetheless, the chatter is enough to move the stock 1.2 percent higher on the session.
The company's new CEO hire John Johnson brings with him an M&A background, having sold ImClone to Eli Lilly in the past, so takeover talk sprouts up quickly and frequently on the name.
In the recent past, Amgen (Nasdaq: AMGN) has been mentioned as a possible suitor.
That is takeover rumors on Provenge maker Dendreon (Nasdaq: DNDN).
Today's rumors are vague and come from what would seem to be unreliable sources. Nonetheless, the chatter is enough to move the stock 1.2 percent higher on the session.
The company's new CEO hire John Johnson brings with him an M&A background, having sold ImClone to Eli Lilly in the past, so takeover talk sprouts up quickly and frequently on the name.
In the recent past, Amgen (Nasdaq: AMGN) has been mentioned as a possible suitor.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) PT Raised to $400 at Cantor Fitzgerald on Higher Sales Estimates
- Amgen (AMGN) PT Raised to $362 at Morgan Stanley
- Critical Metals Corp amends exchange ratio in European Lithium deal
Create E-mail Alert Related Categories
RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
